ECSP034848A - Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes - Google Patents

Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes

Info

Publication number
ECSP034848A
ECSP034848A EC2003004848A ECSP034848A ECSP034848A EC SP034848 A ECSP034848 A EC SP034848A EC 2003004848 A EC2003004848 A EC 2003004848A EC SP034848 A ECSP034848 A EC SP034848A EC SP034848 A ECSP034848 A EC SP034848A
Authority
EC
Ecuador
Prior art keywords
diabetes
treatment
ppar
oxazol
alpha
Prior art date
Application number
EC2003004848A
Other languages
English (en)
Inventor
Markus Boehringer
Markus Meyer
Peter Mohr
Hanspeter Hilpert
Alfred Binggeli
Hans Peter Maerki
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034848A publication Critical patent/ECSP034848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En donde R1 a R7 son como se ha definido en la descripción y las reivindicaciones, y sales farmacéuticamente aceptables y ésteres de los mismos. Los compuestos son útiles para el tratamiento de enfermedades tales como diabetes
EC2003004848A 2001-05-15 2003-11-13 Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes ECSP034848A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15

Publications (1)

Publication Number Publication Date
ECSP034848A true ECSP034848A (es) 2003-12-24

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004848A ECSP034848A (es) 2001-05-15 2003-11-13 Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes

Country Status (39)

Country Link
US (1) US6642389B2 (es)
EP (1) EP1392295B1 (es)
JP (2) JP4330883B2 (es)
KR (1) KR100654516B1 (es)
CN (1) CN100356917C (es)
AR (1) AR035892A1 (es)
AT (1) ATE327753T1 (es)
AU (1) AU2002342244B2 (es)
BG (1) BG66316B1 (es)
BR (1) BRPI0209821B1 (es)
CA (1) CA2445145C (es)
CY (1) CY1105160T1 (es)
CZ (1) CZ20033037A3 (es)
DE (1) DE60211891T2 (es)
DK (1) DK1392295T3 (es)
EC (1) ECSP034848A (es)
EG (1) EG25755A (es)
ES (1) ES2264482T3 (es)
GT (1) GT200200085A (es)
HK (1) HK1067534A1 (es)
HR (1) HRP20030889B1 (es)
HU (1) HU230224B1 (es)
IL (2) IL158589A0 (es)
JO (1) JO2282B1 (es)
MA (1) MA27025A1 (es)
ME (1) ME01310B (es)
MX (1) MXPA03010435A (es)
MY (1) MY136761A (es)
NO (1) NO333833B1 (es)
NZ (1) NZ529033A (es)
PA (1) PA8544901A1 (es)
PE (1) PE20021152A1 (es)
PL (1) PL208074B1 (es)
PT (1) PT1392295E (es)
RU (1) RU2278859C2 (es)
SI (1) SI1392295T1 (es)
SK (1) SK287842B6 (es)
WO (1) WO2002092084A1 (es)
ZA (1) ZA200308538B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1238347C (zh) * 2000-05-26 2006-01-25 日本新药株式会社 杂环衍生物
PL208074B1 (pl) * 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
CA2506112A1 (en) * 2002-11-15 2004-06-03 Cadila Healthcare Limited Substituted aralkyl derivatives
JP4384052B2 (ja) 2002-11-25 2009-12-16 エフ．ホフマン−ラ ロシュ アーゲー インドリル誘導体
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
SG148154A1 (en) 2003-11-05 2008-12-31 Hoffmann La Roche Benzannelated compounds as ppar activators
BRPI0416283A (pt) 2003-11-05 2007-01-23 Hoffmann La Roche compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
DE602005015962D1 (de) 2004-05-03 2009-09-24 Hoffmann La Roche Indolylderivate als liver-x-rezeptormodulatoren
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
ES2390620T3 (es) * 2008-03-10 2012-11-14 Nestec S.A. Ácidos dicarboxílicos de cadena mediana y sus derivados y trastornos metabólicos
US20110124661A1 (en) * 2008-05-15 2011-05-26 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
KR101285520B1 (ko) 2008-12-23 2013-07-17 에프. 호프만-라 로슈 아게 만성 질병을 가진 환자의 진단 또는 치료 지원을 위한 구조화된 테스팅 방법 및 그 디바이스
JP5619027B2 (ja) * 2009-01-23 2014-11-05 エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アレグリタザルを含む医薬組成物
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
EP2585452B1 (en) 2009-12-07 2015-09-23 F.Hoffmann-La Roche Ag Process for the preparation of propionic acid derivatives
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
JP2015528476A (ja) * 2012-09-12 2015-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ （Ｓ）−２−メトキシ−３−｛４−［２−（５−メチル−２−フェニル−オキサゾール−４−イル）−エトキシ］−ベンゾ［ｂ］チオフェン−７−イル｝−プロピオン酸の及びその塩の固体形態
EP3402482A1 (en) 2015-11-18 2018-11-21 H. Hoffnabb-La Roche Ag Aleglitazar for the treatment of diabetic kidney disease
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
KR20240047401A (ko) * 2021-08-13 2024-04-12 알레번드 파마슈티칼스 (홍콩) 리미티드 중수소화 화합물
WO2024100051A1 (en) 2022-11-08 2024-05-16 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
NZ253742A (en) 1992-07-03 1997-06-24 Smithkline Beecham Plc Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
NZ335910A (en) 1996-12-10 2000-11-24 Bristol Myers Squibb Co Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents useful in treating sleep disorders and circadian rhthym related disorders
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
EP0903343B1 (en) 1997-09-19 2003-05-28 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
EP1313716B1 (en) * 2000-08-23 2007-05-02 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
PL208074B1 (pl) * 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu

Also Published As

Publication number Publication date
PE20021152A1 (es) 2003-02-07
GT200200085A (es) 2003-01-16
SK13852003A3 (en) 2004-10-05
HRP20030889A2 (en) 2005-08-31
CY1105160T1 (el) 2009-11-04
PA8544901A1 (es) 2003-01-24
ATE327753T1 (de) 2006-06-15
JP4330883B2 (ja) 2009-09-16
JP2009138011A (ja) 2009-06-25
AR035892A1 (es) 2004-07-21
CZ20033037A3 (cs) 2004-06-16
BG108362A (bg) 2005-03-31
NZ529033A (en) 2005-06-24
PT1392295E (pt) 2006-09-29
SK287842B6 (sk) 2011-12-05
IL158589A0 (en) 2004-05-12
HU230224B1 (hu) 2015-10-28
CA2445145C (en) 2008-10-14
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
JO2282B1 (en) 2005-09-12
NO20035086L (no) 2003-11-14
DE60211891T2 (de) 2007-05-24
CN1509173A (zh) 2004-06-30
ZA200308538B (en) 2005-04-26
ME01310B (me) 2011-10-10
WO2002092084A1 (en) 2002-11-21
KR20030096397A (ko) 2003-12-24
MXPA03010435A (es) 2004-03-09
DE60211891D1 (de) 2006-07-06
JP2004529174A (ja) 2004-09-24
MY136761A (en) 2008-11-28
CN100356917C (zh) 2007-12-26
HUP0400992A2 (hu) 2004-08-30
ES2264482T3 (es) 2007-01-01
US6642389B2 (en) 2003-11-04
BR0209821A (pt) 2004-06-01
MA27025A1 (fr) 2004-12-20
EP1392295B1 (en) 2006-05-31
EP1392295A1 (en) 2004-03-03
AU2002342244B2 (en) 2005-06-16
DK1392295T3 (da) 2006-10-02
BG66316B1 (bg) 2013-04-30
HK1067534A1 (en) 2005-04-15
RU2003134150A (ru) 2005-06-10
BRPI0209821B1 (pt) 2016-09-27
SI1392295T1 (sl) 2006-10-31
HRP20030889B1 (en) 2011-10-31
US20030055265A1 (en) 2003-03-20
NO20035086D0 (no) 2003-11-14
KR100654516B1 (ko) 2006-12-05
NO333833B1 (no) 2013-09-30
HUP0400992A3 (en) 2007-11-28
PL208074B1 (pl) 2011-03-31
CA2445145A1 (en) 2002-11-21
EG25755A (en) 2012-06-26
IL158589A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
ECSP034848A (es) Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes
AR023971A1 (es) Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales
UY28892A1 (es) Inhibidores selectivos de la enzima dipeptidilpeptidasa-iv (dpp-iv) composiciones farmaceuticas de las mismas y su uso terapeutico
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
PA8496301A1 (es) Inhibidores de metaloproteasas.
CL2012000001A1 (es) Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros.
ECSP045193A (es) "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"
GT200000216A (es) Oxazolidinonas sustituidas y su uso.
PE20061153A1 (es) Compuestos heterociclicos como inhibidores del factor viia
UY27388A1 (es) Nuevos compuestos
SV2003001099A (es) Nuevos derivados de acido sulfonico ref.pc23084
ECSP093680A (es) Proceso para derivados del acido fenilacetico
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
PA8581701A1 (es) Derivados de indolilo
UY26847A1 (es) Derivados de la pirrolidina
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
HN2003000015A (es) Sales estables del acido o acetilsalicilico con aminoacidos basicos i i.
UY26846A1 (es) Derivados de la pirrolidina
CR10506A (es) Derivados de acido fenilacetico
ES2190985T3 (es) Tratamiento de migraña por administracion de acido alfa-lipoico o de derivados del mismo.
AR015518A1 (es) Uso de derivados de tiadiazolo piridina para la produccion de un medicamento para el tratamiento de enfermedades que se modulan mediante la inhibicion delas fosfodiesterase(s)
PA8522401A1 (es) Derivados de pirrolidina